Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.50 |
| ▸ | RELA | Q04206 | 5/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8355012 | 1.00 | GAA (0.55) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL1661966 | 1.00 | GAA (0.55) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL10054766 | 0.86 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL7801965 | 0.84 | GAA (0.37) | GAANFKB1NFKB2RELA | |
| SCHEMBL7403132 | 0.84 | GAA (0.37) | GAANFKB1NFKB2RELA | |
| SCHEMBL7403136 | 0.84 | GAA (0.37) | GAANFKB1NFKB2RELA | |
| SCHEMBL29217279 | 0.84 | GAA (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL19021605 | 0.84 | GAA (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL14159811 | 0.79 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL14308598 | 0.78 | GAA (0.47) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283990-B | Application of substituted pyrrolidone compound as tumor necrosis factor inhibitor | 沈阳药科大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-116283990-A | Application of substituted pyrrolidone compound as tumor necrosis factor inhibitor | 沈阳药科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-8735582-B2 | Method for producing carboxylic anhydride and arylboronic acid compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735582-B2 | Method for producing carboxylic anhydride and arylboronic acid compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20110319620-A1 | METHOD FOR PRODUCING CARBOXYLIC ANHYDRIDE AND ARYLBORONIC ACID COMPOUND | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1963319-A1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| US-7390909-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20080091032-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2008-04-17 | — | — | US | disclosed |
| WO-2007071621-A1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-0638068-A1 | PROCESS FOR THE MANUFACTURE OF (S)-3-AMINO-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993022283-A1 | PROCESS FOR THE MANUFACTURE OF (S)-3-AMINO-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| US-5250704-A | Process for the manufacture of (S)-3-amino-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319620-A1 | METHOD FOR PRODUCING CARBOXYLIC ANHYDRIDE AND ARYLBORONIC ACID COMPOUND | CA6, CA9, APEH | GAA 70/4885NFKB1 1476/4885NFKB2 1120/4885 |
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | GAA 195/4885NFKB1 4398/4885NFKB2 4642/4885 |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | GAA 3299/4885NFKB1 2470/4885NFKB2 2280/4885 |
| US-20080091032-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | GAA 195/4885NFKB1 4398/4885NFKB2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.